Severing the Gordian knot of prevention of cytomegalovirus in liver transplant recipients: The principle is the sword

Liver Transplantation

Volumn 11, Issue 8, 2005, Pages 891-894

  Singh, Nina ^a   Yu, Victor L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG COST; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT INDICATION;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; LIVER TRANSPLANTATION; METAPHOR;

EID: 23744497486     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20483     Document Type: Article

References (25)

1. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996;22:537-549.
2. Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Kennedy EM, Langnas AN, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989;124:1443-1450.
3. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001;32:742-751.
4. Falagas ME, Snydman DR, Griffith J, Werner BG, and the Boston Center for Liver Transplantation CMVIG Study Group. Exposure to cytomegalovirus from donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 1996;23:468-474.
5. Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wright DGD, Alexander GJM. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000;69:30-35.
6. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJ, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992;16:285.
7. Madalosso C, De Souza NF, Ilstrup DM, Wiesner RH, Krom RAF. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998;66: 294-297.
8. Kim WR, Badley AD, Wiesner RH, Porayko MK, Seaberg EC, Keating MR, et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000;69: 357-361.
9. Kalil AC, Levitsky J, Lyden E, Stoner J, Lesiak B, Bargenquast K, et al. Preemptive therapy (PRE) and universal prophylaxis (PRO) for cytomegalovirus (CMV) in solid organ transplant recipients (SOT): a meta-analysis. 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004. (Abstract #631).
10. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995;60:1473-1477.
11. Lowance D, Neumayer H-H, Legendre M, Squifflet J-P, Kovarik J, Brennan PJ, et al. For the International Valacylovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-1470.
12. Munoz-Price LS, Slifkin M, Ruthazer R, Poutsiaka DD, Hadley S, Freeman R, et al. The clinical impact of ganciclovir prophylaxis on occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004;39:293-299.
13. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995;346:69-74.
14. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-1733.
15. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli IV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005;79:1428-1434.
16. Kusne S, Grossi P, Irish W, St. George K, Rinaldo C, Rakela J, Fung J. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999;68:1125-1131.
17. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed preemptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus diseases in liver transplant recipients: a randomized, controlled trial. Transplantation 2000;70:717-712.
18. Kelly J, Hurley D, Raghu G, and the University of Washington Lung Transplant Program. Comparison of the cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000;19:355-359.
19. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000;97:8039-8044.
20. Bouza E, Sousa D, Muñoz P, Rodriquez-Créixems M, Fron C, Luchuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004;39:1161-1169.
21. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. On behalf of the Valganciclovir and Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-620.
22. Akalin E, Bromberg JS, Shegal V, Ames S, Daly L, Murphy B. 6 months valganciclovir prophylaxis significantly decreases cytomegalovirus infection incidence in thymoglobulin treated transplant patients. Am J Transplant 2004;4:495.
23. Levitsky J, Freifeld AG, Bargenquast K, Stevens B, Kalil AC. The clinical value to quantitative polymerase chain reaction in cytomegalovirus infection after solid organ transplantation. Am J Transplant 2004;4:339.
24. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M. Late-onset CMV disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004;78:9-16.
25. Singh N, Gayowski T, Wagener MM, Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005;79:85-90.